Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth
One of the main limitations of the vaccination of neonates from vaccinated or infected mothers is the interference by inherited maternal antibodies, which are known to inhibit the immune response against both live and inactivated vaccines. The efficiency of bypassing this inhibition by the transfer of an immunogenic glycoprotein gene, the gD gene of pseudorabies virus (PRV), into neonates was explored. The experiments were conducted in 1- day-old piglets, which are immunocompetent at birth. The same transcription unit (gD of PRV under the control of the adenovirus major late promoter) was delivered intramuscularly at birth either in the form of naked DNA or cloned in the genome of a replication-defective adenovirus. A booster injection of a conventional live PRV vaccine strain was given at 10 weeks of age, the replication of which was greatly restricted by the residual amounts of colostral antibodies in control animals. Piglets were challenged at the age of 16 weeks with a virulent PRV strain. The replication-defective adenovirus was able to efficiently prime piglets born to immune dams against gD in such a way that inoculation with the Bartha strain protected them against a subsequent challenge with the same level of efficacy in piglets born to naive or immune dams. In contrast, piglets born to immune dams into which the gD gene was not transferred, or transferred as naked DNA at birth, were not protected. These results open the way for early immunization of neonates born to vaccinated or infected mothers.
AdamM., Le PotierM. F., EloitM.1994; Vaccination of pigs with replication-defective adenovirus vectored vaccines : the example of pseudorabies. Veterinary Microbiology 42:205–215
AmbriovicA., AdamM., MonteilM., PaulinD., EloitM.1997; Efficacy of replication defective vectored vaccines: protection following intramuscular injection is linked to promoter efficiency in muscle representative cells. Virology in press
AndriesK., PensaertM. B., VandeputteJ.1978; Effect of experimental infection with pseudorabies (Aujeszky’s disease) virus on pigs with maternal immunity from vaccinated sows. American Journal of Veterinary Research 39:1282–1285
CoeN. E., MengelingW. L.1990; Mapping and characterization of neutralizing epitopes of glycoproteins gIII and gp50 of the Indiana-Funkhauser strain of pseudorabies virus. Archives of Virology 110:137–142
DavisH. L., WhalenR. G.1995; DNA-based immunization. In Molecular and Cell Biology of Human Gene Therapeutics pp. 368–387DicksonG. Edited by London: Chapman & Hall;
EloitM., FargeaudD., L’HaridonR., TomaB.1988; Identification of pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodies. Archives of Virology 99:45–56
EloitM., FargeaudD., VannierP., TomaB.1989; Development of an ELISA test to differentiate between animals either vaccinated with or infected by Aujeszky’s disease virus. Veterinary Record 28:91–94
EloitM., Gilardi-HebenstreitP., TomaB., PerricaudetM.1990; Construction of a defective adenovirus vector expressing the pseudorabies virus gp50 and its use as a live vaccine. Journal of General Virology 71:2179–2183
GanneV., EloitM., LavalA., AdamM., TrouveG.1994; Enhancement of the efficacy of a replication defective adenovirus vectoredvaccine by the addition ofoil adjuvants. Vaccine 12:1190–1196
GhiasiH., CaiS., SlanimaS., NesburnA. B., WechslerS. L.1996; Vaccination of mice with herpes simplex type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Research 28:147–157
GilgenkrantzH., DubocD., JuillardV., CoutonD., PaviraniA., GuilletJ. G., BriandP., KahnA.1995; Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors - role of the immune response. Human Gene Therapy 6:1265–1274
GrahamF. L., SmileyJ., RusselW. C., NairnR.1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology 36:59–72
HaddadaE., LopezM., MartinacheC., RagotT., AbinaM. A., PerricaudetM.1993; Efficient adenovirus-mediated gene transfer into human blood monocyte-derived macrophages. Biochemical and Biophysical Research Communications 3:1174–1183
IshiiH., KobayashiY., KurokiM., KodamaY.1988; Protection of mice from lethal infection with Aujeszky’s disease virus by immunization with purified gVI. Journal of General Virology 69:1411–1414
JuillardV., VillefroyP., GodfrinD., PaviraniA., VenetA., GuilletJ. G.1995; Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. European Journal of Immunology 25:3467–3473
KasseislerA., FalckpedersenE., ElfenbeinD. H., AlviraM., ButtrickP. M., LeinwandL. A.1994; The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Therapy 1:395–402
MarchioliC., YanceyR., PetrovskisE., TimminsJ., PostL.1987; Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky’s disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells. Journal of Virology 61:3977–3982
MonteilM., Le PotierM. F., GuillotinJ., CarioletR., HoudayerC., EloitM.1996; Genetic immunization of seronegative one-day-old piglets against pseudorabies induces neutralizing antibodies but not protection and is ineffective in piglets from immune dams. Veterinary Research 27:443–452
RiviereM., TartagliaJ., PerkusM., NortonE., BongerminoC., LacosteF., DuretC., DesmettreP., PaolettiE.1992; Protection of mice and swine from pseudorabies virus by vaccinia virus-based recombinants. Journal of Virology 66:3424–3434
StellmannC., VannierP., ChappuisG., BrunA., DauvergneM., FargeaudD., BugandM., ColsonX.1989; The potency testing of pseudorabies vaccines in pigs. A proposal for a quantitative criterion and a minimum requirement. Journal of Biological Standards 17:17–27
UlmerJ. B., DonellyJ., ParkerS. E., RhodesG. H., FelgnerP. L., DwarkiV. J., GromkowskiS. H., DeckR. R., DewittC. M., FriedmanA., HaweL. A., LeanderK. R., MartinezD., PerryH. C., ShiverJ. W., MontgomeryD. L., LiuM. A.1993; Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749
UlmerJ. B., DeckR. R., DewittC. M., FriedmanA., DonnellyJ. J., LiuM. A.1994; Protection immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 12:1541–1544
VannierP., HutetE., CarioletR.1995; Influence of passive immunity on pig immunization with deleted Aujeszky’s disease vaccines measured by the amount of wild virus excretion after challenge. Veterinary Microbiology 43:53–63
WathenM. W., WathenL. M. K.1984; Isolation, characterisation and physical mapping of a pseudorabies virus mutant containing antigenically altered gp50. Journal of Virology 51:57–62
YangY. P., NunesF. A., BerencsiK., GonczolE., EngelhardtJ. F., WilsonJ. M.1994; Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genetics 7:362–369
Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth